Hester Biosciences Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - Rajiv Gandhi and other management representatives referred to debt repayment, indicating existing debt reduction efforts (e.g., Rs. 25-30 crores being paid annually, and Rs. 30 crores debt reduced recently). - Management emphasized focusing on improving profitability and operational performance rather than new fundraising. - No explicit plans or discussions about raising fresh capital via debt or equity were disclosed during the call.

- Rs. 168 crores of capital work-in-progress primarily related to: - BSL-3 facility at Hester India plant (originally for COVID vaccine production, now being repurposed for veterinary vaccines). - Fill-finish line, expected to be commercially operational within the next two months. - Completed receipt of all government grants for building BSL-3 facility; no pending grants. - Repurposing BSL-3 facility for commercial production of veterinary vaccines to enhance manufacturing capacity. - Active steps to introduce new products in therapeutics, supplements, prescription, and pet food diet segments to diversify offerings. - Strategic focus on strengthening presence in African veterinary markets with dossiers submitted for additional products (CCPP and Sheep and Goat Pox). - Ongoing efforts to build a robust marketing network in East and Central Africa to support growth. - Investment aimed at expanding capacities and market reach, signaling commitment to sustained growth.

- The poultry industry is on an upswing, leading to increased vaccine uptake as farmers adopt more progressive farming methods. - Animal healthcare industry growth is expected around 8%-9%, with Hester Biosciences targeting 12% standalone growth. - For FY25 and beyond, the company aims to improve both topline (sales/revenue) and bottomline (profitability), working hard to capitalize on market recovery and election year demand. - The African subsidiary loss is expected to improve with gradual market normalization, enabling better order fulfillment and revenue generation. - New product introductions in therapeutics, supplements, pet food diet segments, and specialized poultry products are anticipated to contribute to growth. - The BSL-3 facility and fill-finish line are nearing commercialization, expected to enhance manufacturing capacity and sales in the near term. - Distribution network expansion and improved after-sales monitoring aim to strengthen market position and volume growth.

- The company is optimistic about growth, aiming to reach Rs. 300 crores in size this year and beyond, with strategic focus refined through recent insights. - Animal Health division expects stable profitability with improved topline and focus on bottomline profitability. - The poultry healthcare segment is on an upswing, with expected continued improvement driven by industry recovery and new product introductions. - Overall growth in the animal healthcare industry is around 8-9%; Hester Biosciences has grown at about 12% standalone. - The company is targeting top-line and bottom-line improvements, albeit cautiously due to market uncertainties. - EBITDA and PAT missed growth slightly but showed positive trends; debt reduction by Rs. 30 crores strengthens financial health. - African subsidiary losses are expected to improve as macro conditions normalize, with confidence to return to profitability within the year. - Focus on complementing vaccines with health products may affect margin mix but is seen as strategic for long-term growth.

- The transcript does not explicitly mention a quantified current or expected orderbook or pending orders. - Rajiv Gandhi noted that tenders won in Tanzania could not be supplied due to foreign exchange issues, implying some pending orders. - There is an anticipation of government orders for Hester Africa in the upcoming financial year, focused on East and Central African countries. - The company is building a robust marketing network in African regions to support future orders. - No government grants are pending; all grants related to the BSL-3 facility have been received. - The repurposed BSL-3 facility and fill-finish line are expected to go on stream soon, potentially supporting increased order fulfillment. - Overall, management expresses optimism regarding order inflows as markets recover, though no specific orderbook value is disclosed.